Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Genentech's Tecentriq Shows Promise for First-line Lung Cancer Treatment

2h biospace
Genentech, Inc., a Roche Group company, indicated its IMpower131 Phase III clinical trial of Tecentriq (atezolizumab) with carboplatin and Abraxane met its co-primary endpoint of progression-free survival (PFS) in lung cancer. Although a statistically significant overall survival (OS) benefit wasn’t seen and the study will continue, these results gives Genentech a lead for potentially becoming first-line treatment for squamous non-small cell lung cancer (NSCLC). (16-0)

Pfizer's Xtandi Label Expansion Filing Gets Priority Review

18h zacks
Pfizer Inc. (PFE - Free Report) and its Japanese partner Astellas announced that the FDA has granted priority review to a supplemental new drug application (sNDA) for prostate cancer drug, Xtandi. Pfizer is looking to expand the label of Xtandi to include an early-stage patient population. With the FDA granting priority review, a decision is expected in July. (16-0)

Biotechs Approaching New Waters

18h seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment. (727-2)

FDA Grants Priority Review for Prostrate Cancer Treatment

19h biospace
A little more than one month after Pfizer Inc. and partner Astellas Pharma unveiled impressive Phase III data for the efficacy of Xtandi in non-metastatic Castration-Resistant Prostate Cancer (CRPC), the companies said a supplemental New Drug Application with the U.S. Food and Drug Administration was accepted. (20-0)

Spotting Alzheimer’s Early Could Save America $7.9 Trillion - Bloomberg

23h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (66-0)

Nick's Portfolio Tournament First Round Results

2018-03-19 seekingalpha
Alright basketball fans and portfolio managers, here we have it: the first round results of the 2018 Nick's Portfolio Tournament. For those of you who missed it, I said out the selection committee's decision in this introductory piece a week ago. First of all, let me preface this piece by saying that this was a bit of a marathon type-fest, so I ask that you please forgive any typos ahead of time. Secondly, I want to re-hash the competition criteria. (632-0)

Study Reveals Huge Potential for mRNA Drug Targets

2018-03-19 biospace
Companies that have a strong focus on developing drugs that target messenger RNA (mRNA) may be ahead of the curve when it comes to potentially tapping into a lucrative market space. (16-0)

6 Biotech Companies with Upside Potential

2018-03-19 biospace has come out with a report noting certain research-and-development spending trends that are expected to stimulate biotech development. And in that context, they note six biotech companies that they believe will benefit the most from those trends. (50-0)

Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration | Nature Biotechnology

2018-03-19 nature
Age-related macular degeneration (AMD) remains a major cause of blindness, with dysfunction and loss of retinal pigment epithelium (RPE) central to disease progression. We engineered an RPE patch comprising a fully differentiated, human embryonic stem cell (hESC)–derived RPE monolayer on a coated, synthetic basement membrane. We delivered the patch, using a purpose-designed microsurgical tool, into the subretinal space of one eye in each of two patients with severe exudative AMD. (16-0)

J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit

2018-03-19 zacks
Johnson & Johnson (JNJ - Free Report) announced that it has received a binding offer of approximately $2.1 billion from a private equity firm, Platinum Equity, for its LifeScan diabetes device unit. The LifeScan unit makes blood glucose monitoring products and generated revenues of $1.5 billion last year. (95-0)

Should Value Investors Pick Pfizer (PFE) Stock Now?

2018-03-19 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. (18-0)

Pfizer Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-03-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (16-0)

Biogen's Key Variable: Its Neuroscience Pipeline

2018-03-18 seekingalpha
Biogen (NASDAQ:BIIB) is best known for its MS (multiple sclerosis) therapies. While Biogen is set to remain a major player in that setting, its future expansion will likely be in other neural diseases. (165-0)

US to cover advanced genomic testing for Medicare cancer patients - Channel NewsAsia

2018-03-16 channelnewsasia
REUTERS: The U.S. government said on Friday it will pay for certain genetic tests for Medicare-eligible patients with advanced cancer, in a bid to help match patients with the drugs most likely to provide benefit. (23-0)

U.S. to cover advanced genomic testing for Medicare cancer patients

2018-03-16 reuters
(Reuters) - The U.S. government said on Friday it will pay for certain genetic tests for Medicare-eligible patients with advanced cancer, in a bid to help match patients with the drugs most likely to provide benefit. (23-0)

CUSIP: 717081103